GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Heidelberg Pharma AG (XTER:HPHA) » Definitions » Shares Outstanding (EOP)

Heidelberg Pharma AG (XTER:HPHA) Shares Outstanding (EOP) : 46.61 Mil (As of Feb. 2024)


View and export this data going back to 2006. Start your Free Trial

What is Heidelberg Pharma AG Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Heidelberg Pharma AG's shares outstanding for the quarter that ended in Feb. 2024 was 46.61 Mil.

Heidelberg Pharma AG's quarterly shares outstanding stayed the same from Nov. 2023 (46.61 Mil) to Feb. 2024 (46.61 Mil).

Heidelberg Pharma AG's annual shares outstanding increased from Nov. 2022 (46.58 Mil) to Nov. 2023 (46.61 Mil). It means Heidelberg Pharma AG issued new shares from Nov. 2022 to Nov. 2023 .


Heidelberg Pharma AG Shares Outstanding (EOP) Historical Data

The historical data trend for Heidelberg Pharma AG's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Heidelberg Pharma AG Shares Outstanding (EOP) Chart

Heidelberg Pharma AG Annual Data
Trend Nov14 Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 28.21 31.06 34.18 46.58 46.61

Heidelberg Pharma AG Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 46.58 46.60 46.61 46.61 46.61

Competitive Comparison of Heidelberg Pharma AG's Shares Outstanding (EOP)

For the Biotechnology subindustry, Heidelberg Pharma AG's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Heidelberg Pharma AG's Shares Outstanding (EOP) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Heidelberg Pharma AG's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Heidelberg Pharma AG's Shares Outstanding (EOP) falls into.



Heidelberg Pharma AG Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Heidelberg Pharma AG  (XTER:HPHA) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Heidelberg Pharma AG Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Heidelberg Pharma AG's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Heidelberg Pharma AG (XTER:HPHA) Business Description

Traded in Other Exchanges
Address
Gregor-Mendel-Street 22, Ladenburg, DEU, 68526
Heidelberg Pharma AG is a biopharmaceutical company. It is focused on oncology and develops the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform and advances the biological mode of action of the toxin as a novel therapeutic principle. The proprietary lead candidate is HDP-101 which is a BCMA (B-cell maturation antigen) - ATAC for multiple myeloma. In addition, the company offers preclinical contract research services. It operates through the following business divisions: Customer Specific Research, Diagnostics, and TherapeuticS.
Executives
Prof. Dr. Andreas Pahl Board of Directors

Heidelberg Pharma AG (XTER:HPHA) Headlines

No Headlines